Effectiveness of Eribulin as First-Line or Second-Line Chemotherapy for HER2-Negative Hormone-Resistant Advanced or MBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Breast Cancer (Tokyo, Japan)
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study
Breast Cancer 2022 Apr 23;[EPub Ahead of Print], Y Kikawa, T Kotake, S Tsuyuki, Y Kang, S Takahara, Y Fujimoto, H Yamashiro, H Yoshibayashi, M Takada, R Yasuoka, K Nakatsukasa, K Yamagami, H Suwa, T Okuno, I Nakayama, T Kato, N Ogura, Y Moriguchi, H Ishiguro, T Kagimura, T Taguchi, T Sugie, M ToiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.